Life Sciences

  • September 13, 2024

    Sandoz Awarded $137M In Generic Hypertension Drug Fight

    United Therapeutics Corp. owes Sandoz Inc. $137.2 million for conduct that breached an earlier settlement agreement between the parties and effectively blocked the sale of Sandoz's generic version of an injectable drug to treat hypertension, a New Jersey federal judge has ruled.

  • September 13, 2024

    Walgreens To Pay $107M To End 3 False Billing Claims Suits

    Walgreens has agreed to pay $106.8 million to settle claims across three lawsuits that it violated the False Claims Act and state laws for billing government health programs for prescriptions it never dispensed, the U.S. Department of Justice announced Friday.

  • September 13, 2024

    Judge Orders Mobile IV Co. To Stop Eli Lilly Infringment

    A Colorado-based mobile outfit that administers IV treatments to customers in their homes must stop all advertising and web promotion that gives the impression it offers Eli Lilly medications, according to a settlement approved by a federal judge.

  • September 13, 2024

    EU Actors Lobby Hard For Top Jobs in New Commission

    European Union lawmakers and national governments are lobbying intensely to pull top jobs and policy their way as the new European Commission is formed for the next five years.

  • September 13, 2024

    Kennedys Hires Cyber, AI Pro From Addleshaw In London

    Kennedys Law LLP has recruited a data protection, cybersecurity and artificial intelligence specialist from Addleshaw Goddard LLP as a partner in London, with the new arrival saying Friday she made the switch to take advantage of the firm's global reach.

  • September 13, 2024

    SEC Fines Zymergen $30M Over Misleading Pre-IPO Claims

    Now-shuttered biotechnology company Zymergen Inc. has agreed to pay a $30 million fine to settle U.S. Securities and Exchange Commission allegations that it misled investors in its initial public offering when it used "unsupported hype" about the market potential for its technology for foldable touch screens.

  • September 13, 2024

    Trio Of BigLaw Mergers Expected To Drive More Deal Talks

    After months of a relatively steady pace of law firm mergers and acquisitions, the trio of proposed BigLaw tie-ups announced in recent days will likely spur more firms toward entertaining similar deal talks, experts say. Here, Law360 offers a snapshot of the proposed deals.

  • September 13, 2024

    Emergent BioSolutions Pays $40M To Settle COVID Vax Suit

    Emergent BioSolutions has agreed to pay $40 million to settle a consolidated class action alleging it misled investors about how prepared it was to handle two high-profile deals to manufacture COVID-19 vaccines.

  • September 13, 2024

    Med Techs Settle Eyelid Cleaner Patent Spat

    Two companies specializing in eyelid cleaning technology have reached a deal to settle their dispute in California federal court after the court refused to dismiss the infringement allegations.

  • September 13, 2024

    2 Life Sciences Cos. Start Trading After Raising $540M Total

    Drug developers Bicara Therapeutics Inc. and Zenas BioPharma Inc. have debuted on the Nasdaq stock exchange in separate initial public offerings steered by a trio of law firms.

  • September 13, 2024

    Makers Of Paragard Say Time Ran Out On Claims In 236 Suits

    Teva Pharmaceuticals and The Cooper Cos. pressed an Atlanta federal judge to pare back multidistrict litigation over alleged defects in the Paragard IUD by dismissing untimely claims across 236 complaints.

  • September 13, 2024

    Ex-DOJ Deputy In TikTok, Twitter Cases Joins Mayer Brown

    A former leader of the U.S. Department of Justice's consumer protection arm who helped bring landmark privacy cases against TikTok and Twitter is jumping to Mayer Brown LLP, where he will focus on government investigations and enforcement actions.

  • September 13, 2024

    UK Litigation Roundup: Here's What You Missed In London

    This past week in London has seen a football agent sue Chelsea FC after being cleared of allegations he threatened the club’s former director, an ongoing patent dispute between Amgen and Regeneron Pharmaceuticals, and a private school in Edinburgh suing Riverstone Insurance over compensation claims tied to historical abuse allegations made by former pupils. Here, Law360 looks at these and other new claims in the U.K.

  • September 13, 2024

    NHS Scotland Sues Accord, Allergan Over Drug Pricing

    Scotland has sued Actavis and Allergan to recover the additional money they allegedly charged for hydrocortisone tablets used to treat a rare autoimmune disorder, the specialist antitrust tribunal said Friday after an appeals court reinstated price-fixing fines against the drugmakers.

  • September 13, 2024

    Former MilliporeSigma Patent Atty Joins Polsinelli In St. Louis

    A patent expert and former in-house attorney with chemical and biotechnology company MilliporeSigma has joined Polsinelli PC's St. Louis office, continuing the law firm's expansion of its life sciences team.

  • September 13, 2024

    Ropes & Gray Helps Kohlberg Net $4.3B For 10th PE Fund

    Kohlberg & Co., advised by Ropes & Gray, said Friday it has clinched its 10th flagship fund after raising $4.3 billion from limited partners, with plans to target investments in companies within areas including pharmaceuticals, healthcare and financial and compliance services.

  • September 13, 2024

    French Vaccine Maker Valneva Raises €61M In Private Placing

    Vaccine manufacturer Valneva SE said Friday that it has successfully raised approximately €61.2 million ($67.9 million) by selling shares to investors, which it plans to use to fund projects.

  • September 13, 2024

    Alcon Loses European Patent Over Eye Imaging Tech

    European officials have stripped Alcon Inc. of its protections over an eye-imaging device, ruling that the company's amended description of the technology's "ray tracing" process unlawfully broadened the patent.

  • September 12, 2024

    Wilson Sonsini Hires Tax Pro From Slaughter and May

    Wilson Sonsini Goodrich & Rosati PC has recruited a tax specialist from Slaughter and May to its office in London to boost its strengths representing U.K. and European technology and life sciences companies that are expanding in the U.S. and globally.

  • September 12, 2024

    Faegre Drinker Adds White Collar Trio From Greenberg Traurig

    Faegre Drinker Biddle & Reath LLP is building out its white collar team with former veteran prosecutors, announcing Wednesday it had added two partners and an associate from Greenberg Traurig LLP who will bolster its San Francisco and Philadelphia offices

  • September 12, 2024

    Mass Tort Boutique Leader On Sizing Up With Anapol Weiss

    Nearly four years after leaving the corporate defense world to launch her own five-attorney plaintiffs' boutique, former Wilkinson Stekloff LLP founding partner Alexandra Walsh says she's looking forward to spending more time in the courtroom as her firm is absorbed by Philadelphia-based mass tort and personal injury firm Anapol Weiss. Here, Law360 Pulse speaks with Walsh about the decision to merge and about her move from the defense to the plaintiffs' bar.

  • September 12, 2024

    Greenberg Traurig Grows Health Team With Ex-NY Official

    A former New York State Department of Health official has moved to the private sector with Greenberg Traurig LLP as the firm expands its healthcare and U.S. Food and Drug Administration practice.

  • September 12, 2024

    Stites & Harbison Eyes Conn. Office With Patent Team Pickup

    Stites & Harbison PLLC is stretching beyond its established offices in the South and Midwest with a planned Connecticut location, thanks to the pickup of three patent attorneys and three patent agents formerly with Cantor Colburn LLP.

  • September 12, 2024

    Sullivan & Cromwell Guides Springer Nature's German IPO

    German-British journal publisher Springer Nature said Thursday that it will aim to raise €200 million ($220 million) as it announced plans for an initial public offering in Frankfurt — what would be the first large European listing in the second half of the year. 

  • September 12, 2024

    Sanofi Sets €320M Licensing Deal With US, French Biotechs

    Pharmaceutical giant Sanofi SA said Thursday that it will pay up to €320 million ($353 million) to U.S. biotechnology group RadioMedix Inc. and French medicine developer Orano Med for an exclusive license for a radiation treatment for rare cancers.

Expert Analysis

  • Opinion

    Now More Than Ever, Lawyers Must Exhibit Professionalism

    Author Photo

    As society becomes increasingly fractured and workplace incivility is on the rise, attorneys must champion professionalism and lead by example, demonstrating how lawyers can respectfully disagree without being disagreeable, says Edward Casmere at Norton Rose.

  • Opinion

    High Court Made Profound Mistake In Tossing Purdue Deal

    Author Photo

    The U.S. Supreme Court's recent decision to throw out Purdue Pharma's Chapter 11 plan jeopardizes a multistate agreement that would provide approximately $7 billion in much-needed relief to help fight the opioid epidemic, with states now likely doomed to spend years chasing individual defendants across the globe, says Swain Wood at Morningstar.

  • Series

    Serving In The National Guard Makes Me A Better Lawyer

    Author Photo

    My ongoing military experience as a judge advocate general in the National Guard has shaped me as a person and a lawyer, teaching me the importance of embracing confidence, balance and teamwork in both my Army and civilian roles, says Danielle Aymond at Baker Donelson.

  • Big Business May Come To Rue The Post-Administrative State

    Author Photo

    Many have framed the U.S. Supreme Court’s recent decisions overturning Chevron deference and extending the window to challenge regulations as big wins for big business, but sand in the gears of agency rulemaking may be a double-edged sword, creating prolonged uncertainty that impedes businesses’ ability to plan for the future, says Todd Baker at Columbia University.

  • Opinion

    Proposed Terminal Disclaimers Rule Harms Colleges, Startups

    Author Photo

    Universities and startups are ill-suited to follow the U.S. Patent and Trademark Office’s recently proposed rule on terminal disclaimers due to their necessity of filing patent applications early prior to contacting outside entities for funds and resources, say attorneys at Sterne Kessler.

  • A Midyear Forecast: Tailwinds Expected For Atty Hourly Rates

    Author Photo

    Hourly rates for partners, associates and support staff continued to rise in the first half of this year, and this growth shows no signs of slowing for the rest of 2024 and into next year, driven in part by the return of mergers and acquisitions and the widespread adoption of artificial intelligence, says Chuck Chandler at Valeo Partners.

  • Critical Questions Remain After High Court's Abortion Rulings

    Author Photo

    The U.S. Supreme Court's decisions in two major abortion-related cases this term largely preserve the status quo for now, but leave federal preemption, the Comstock Act and in vitro fertilization in limbo, say attorneys at Jenner & Block.

  • A Look At Acquisition Trends For Radiopharmaceuticals

    Author Photo

    As radiopharmaceutical drugs are increasingly used for the diagnosis and treatment of certain diseases, interest from Big Pharma entities is following suit, despite some questions around the drugs' capacity to expand beyond their limited niche, says Adrian Toutoungi at Taylor Wessing.

  • Opinion

    States Should Loosen Law Firm Ownership Restrictions

    Author Photo

    Despite growing buzz, normalized nonlawyer ownership of law firms is a distant prospect, so the legal community should focus first on liberalizing state restrictions on attorney and firm purchases of practices, which would bolster succession planning and improve access to justice, says Michael Di Gennaro at The Law Practice Exchange.

  • Navigating FDA Supply Rule Leeway For Small Dispensers

    Author Photo

    As the November compliance deadline for the U.S. Food and Drug Administration's new pharmaceutical distribution supply chain rules draws closer, small dispensers should understand the narrow flexibilities that are available, and the questions to consider before taking advantage of them, say attorneys at Faegre Drinker.

  • Series

    Solving Puzzles Makes Me A Better Lawyer

    Author Photo

    Tackling daily puzzles — like Wordle, KenKen and Connections — has bolstered my intellectual property litigation practice by helping me to exercise different mental skills, acknowledge minor but important details, and build and reinforce good habits, says Roy Wepner at Kaplan Breyer.

  • Texas Ethics Opinion Flags Hazards Of Unauthorized Practice

    Author Photo

    The Texas Professional Ethics Committee's recently issued proposed opinion finding that in-house counsel providing legal services to the company's clients constitutes the unauthorized practice of law is a valuable clarification given that a UPL violation — a misdemeanor in most states — carries high stakes, say Hilary Gerzhoy and Julienne Pasichow at HWG.

  • 6 Lessons From DOJ's 1st Controlled Drug Case In Telehealth

    Author Photo

    Following the U.S. Department of Justice’s first-ever criminal prosecution over telehealth-prescribed controlled substances in U.S. v. Ruthia He, healthcare providers should be mindful of the risks associated with restricting the physician-patient relationship when crafting new business models, says Jonathan Porter at Husch Blackwell.

  • Series

    After Chevron: Scale Tips Favor Away From HHS Agencies

    Author Photo

    The loss of Chevron deference may indirectly aid parties in challenging the U.S. Department of Health and Human Services' interpretations of regulations and could immediately influence several pending cases challenging HHS on technical questions and agency authority, say attorneys at Ropes & Gray.

  • 2 Options For Sackler Family After High Court Purdue Ruling

    Author Photo

    After the U.S. Supreme Court recently blocked Purdue Pharma's plan to shield the family that owns the company from bankruptcy lawsuits, the Sacklers face the choice to either continue litigation, or return to the bargaining table for a settlement that doesn't eliminate creditor claims, says Gregory Germain at Syracuse University.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!